<DOC>
	<DOCNO>NCT00184639</DOCNO>
	<brief_summary>This trial conduct Europe . A 32-week efficacy safety comparison insulin detemir insulin semilente MC child 6 21 year type 1 diabetes .</brief_summary>
	<brief_title>Comparison Insulin Detemir Insulin Semilente®MC Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Type 1 diabetes Current intensify insulin treatment Injection insulin Semilente®MC bedtime least 6 week BMI maximum 32 kg/m^2 HbA1c &gt; 5.5 % &lt; 12.0 % Current treatment premixed insulin ( ) Impaired hepatic renal function Recurrent major hypoglycaemia</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>